Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. B-ultrasound or magnetic resonance imaging (MRI) examination confirmed that the subject has adenomyosis, and the uterus is less than 10 weeks of pregnancy;~2. Visual analogue scale (VAS) of adenomyosis-associated pain\> 0 points; with or without menorrhagia (PBAC≥100 points);~3. Women between 18 and 50 years old who currently have no childbearing requirements;~4. Normal or cervical cytology results without clinical significance (results within 6 months before the screening period);~5. Willing to choose a barrier method of contraception if contraception is needed;~6. Be tested voluntarily and sign the informed consent.~7. No menopause~No menopause~Exclusion Criteria:~1. HB\<90G/L~2. Undiagnosed abnormal vaginal bleeding or endometrial lesions;~3. Pregnancy and lactation women and those who are preparing to give birth when taking the medication or within 6 months of stopping the medication;~4. Malignant tumors (including the reproductive system and other systems);~5. The patients with severe heart, liver, kidney disease and adrenocortical insufficiency;~6. The results of follow-up laboratory test indicate abnormal clinical significance;~7. The allergic persons or those who have been allergic to multiple drugs, or are allergic to active ingredients or any excipients of the study drug;~8. Suffering from any disease or condition that may cause the study drug to alter absorption, accumulate excessively, affect metabolism, or change the excretion pattern;~9. Having clinically significant depression within the current or most recent year;~10. People who regularly take analgesics due to other underlying diseases;~11. Ketoconazole, itraconazole, erythromycin, rifampicin, corticosteroids (hydrocortisone, prednisone, dexamethasone, etc.), and some anticonvulsants (phenytoin, phenobarbital, carbamazepine, etc.), griseofulvin, non-steroidal anti-inflammatory drugs (aspirin, acetaminophen, etc.) that are being used and cannot be stopped during the study;~12. Previous use of hormone drugs, including: a. use of GnRH agonists within 6 months before the screening period; b. use of progestins or danazol and other long-acting hormones within 3 months before the screening period; c. use of oral contraceptive-like short-acting hormones within one month before the screening period;~13. Patients who participated in other clinical trials within 3 months before the screening, or who are considered inappropriate to participate in the study by other investigators.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- study group (Type: EXPERIMENTAL): mifepristone tablets ，10mg，One tablet daily, oral treatment
- control group (Type: PLACEBO_COMPARATOR): placebo，10mg，One tablet daily, oral treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete